{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T00:20:16Z","timestamp":1795134016120,"version":"4.10.3"},"reference-count":53,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This exploratory analysis assessed predictive biomarkers for sacituzumab govitecan (SG) in the open-label, phase III EVOKE-01 study of SG versus docetaxel in non\u2013small cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Trophoblast cell-surface antigen (Trop) 2 membrane protein expression was analyzed using immunohistochemistry in the Trop-2 biomarker-evaluable population (BEP). Circulating tumor DNA (ctDNA) analyses evaluated baseline and reduction of ctDNA with treatment and identified oncogenic driver alterations (KRAS, TP53, KEAP1, and STK11) and other relevant mutations in the ctDNA BEP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The median overall survival (OS) with SG versus docetaxel was 8.9 versus 9.8 months [hazard ratio (HR) = 0.96; 95% CI, 0.68\u20131.38] and 11.8 versus 10.7 months (HR = 0.89; 95% CI, 0.60\u20131.32) in subgroups with Trop-2 histologic scores greater than or equal to the median and less than the median, respectively. As expected, the median OS was longest in patients with undetectable baseline ctDNA. Reduction in ctDNA was observed after the first cycle with either treatment. KRAS driver alterations and potential immunotherapy resistance mutations (TP53, KEAP1, and STK11) were negative prognostic factors. Patients with TP53 mutations derived more benefit from SG than docetaxel. SG activity was observed independent of DNA damage repair (DDR) mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Trop-2 expression did not identify patients benefiting more from SG than from docetaxel. ctDNA reduction supported SG as active therapy in NSCLC. Evaluation of clinically relevant biomarkers in NSCLC identified KRAS, TP53, STK11, and KEAP1 mutations as negative prognostic factors in these second line\u2013treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The biomarker analyses of the phase III EVOKE-01 trial found that neither Trop-2 expression nor DDR alterations predicted benefit with SG versus docetaxel. Reduction in ctDNA in both treatment arms confirmed the activity of SG in this population. Further evaluation of predictive biomarkers for SG response in NSCLC is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0070","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:51:54Z","timestamp":1784065914000},"page":"1875-1888","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non\u2013Small Cell Lung Cancer: Insights From the EVOKE-01 Study"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7620-0098","authenticated-orcid":false,"given":"Enriqueta","family":"Felip","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03ba28x55","id-type":"ROR","asserted-by":"publisher"}],"name":"Vall d\u2019Hebron University Hospital 1 , Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5567-4194","authenticated-orcid":false,"given":"Peiwen","family":"Kuo","sequence":"additional","affiliation":[{"name":"2Gilead Sciences, Inc., Foster City, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5899-6125","authenticated-orcid":false,"given":"Pilar","family":"Garrido","sequence":"additional","affiliation":[{"name":"3Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-5524","authenticated-orcid":false,"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[{"name":"4Service de Pneumologie, Centre Hospitalier Intercommunal de Cr\u00e9teil, Cr\u00e9teil, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-7836","authenticated-orcid":false,"given":"Giannis","family":"Mountzios","sequence":"additional","affiliation":[{"name":"5Henry Dunant Hospital Center, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-8465","authenticated-orcid":false,"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[{"name":"6Department of Medicine and Surgery, University of Parma, Parma, Italy."},{"name":"7Medical Oncology Unit, University Hospital of Parma, Parma, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-0119","authenticated-orcid":false,"given":"Davey B.","family":"Daniel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03754ky26","id-type":"ROR","asserted-by":"publisher"}],"name":"Tennessee Oncology 8 , Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1090-2405","authenticated-orcid":false,"given":"Marianna","family":"Zavodovskaya","sequence":"additional","affiliation":[{"name":"2Gilead Sciences, Inc., Foster City, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8224-2809","authenticated-orcid":false,"given":"Shan","family":"Tang","sequence":"additional","affiliation":[{"name":"2Gilead Sciences, Inc., Foster City, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-7925","authenticated-orcid":false,"given":"Linda","family":"Su-Feher","sequence":"additional","affiliation":[{"name":"2Gilead Sciences, Inc., Foster City, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2507-6826","authenticated-orcid":false,"given":"Riddhi","family":"Patel","sequence":"additional","affiliation":[{"name":"2Gilead Sciences, Inc., Foster City, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1699-3951","authenticated-orcid":false,"given":"Joseph K.","family":"Park","sequence":"additional","affiliation":[{"name":"2Gilead Sciences, Inc., Foster City, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8438-2429","authenticated-orcid":false,"given":"Juliane M.","family":"J\u00fcrgensmeier","sequence":"additional","affiliation":[{"name":"2Gilead Sciences, Inc., Foster City, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1691-4629","authenticated-orcid":false,"given":"Yvonne","family":"Summers","sequence":"additional","affiliation":[{"name":"9The Christie NHS Foundation Trust, Manchester, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"2026080609160870300_bib1","volume-title":"Prescribing information","author":"Trodelvy\u00ae","year":"2025"},{"key":"2026080609160870300_bib2","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"2026080609160870300_bib3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications","volume":"6","author":"Shvartsur","year":"2015","journal-title":"Genes Cancer"},{"key":"2026080609160870300_bib4","doi-asserted-by":"publisher","first-page":"e0321555","DOI":"10.1371\/journal.pone.0321555","article-title":"Trop-2 expression in non\u2013small cell lung cancer","volume":"20","author":"Kuo","year":"2025","journal-title":"PLoS One"},{"key":"2026080609160870300_bib5","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026080609160870300_bib6","doi-asserted-by":"publisher","first-page":"23523735251317865","DOI":"10.1177\/23523735251317865","article-title":"Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer","volume":"11","author":"Shanmugam","year":"2025","journal-title":"Bladder Cancer"},{"key":"2026080609160870300_bib7","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1200\/jco.2024.42.16_suppl.1075","article-title":"Genomic alterations in DNA damage response (DDR) genes in HR+\/HER2\u2212 metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): biomarker results from TROPICS-02 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026080609160870300_bib8","doi-asserted-by":"publisher","first-page":"28725","DOI":"10.18632\/oncotarget.15647","article-title":"Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes","volume":"8","author":"Inamura","year":"2017","journal-title":"Oncotarget"},{"key":"2026080609160870300_bib9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbrc.2016.01.032","article-title":"TROP2 overexpression promotes proliferation and invasion of lung adenocarcinoma cells","volume":"470","author":"Li","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"2026080609160870300_bib10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00428-010-0930-8","article-title":"Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma","volume":"457","author":"Kobayashi","year":"2010","journal-title":"Virchows Archiv"},{"key":"2026080609160870300_bib11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","article-title":"Trop2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non\u2013small cell lung cancer","volume":"30","author":"Bessede","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026080609160870300_bib12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2021.12.010","article-title":"TDP1 and TOP1 as targets in anticancer treatment of NSCLC: activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data","volume":"164","author":"Jakobsen","year":"2022","journal-title":"Lung Cancer"},{"key":"2026080609160870300_bib13","doi-asserted-by":"publisher","first-page":"e0174515","DOI":"10.1371\/journal.pone.0174515","article-title":"Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan\u2013Meier plotter","volume":"12","author":"Hou","year":"2017","journal-title":"PLoS One"},{"key":"2026080609160870300_bib14","doi-asserted-by":"publisher","first-page":"4954","DOI":"10.3390\/cancers14194954","article-title":"Prognostic value of circulating tumor DNA (ctDNA) in oncogene-driven NSCLC: current knowledge and future perspectives","volume":"14","author":"Zografos","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026080609160870300_bib15","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1080\/14796694.2024.2376513","article-title":"Clinical application of ctDNA in early diagnosis, treatment and prognosis of patients with non-small cell lung cancer","volume":"20","author":"Zhu","year":"2024","journal-title":"Future Oncol"},{"key":"2026080609160870300_bib16","doi-asserted-by":"publisher","first-page":"e001504","DOI":"10.1136\/jitc-2020-001504","article-title":"Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)","volume":"9","author":"Ricciuti","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026080609160870300_bib17","doi-asserted-by":"publisher","first-page":"1253629","DOI":"10.3389\/fonc.2023.1253629","article-title":"ctDNA-based detection of molecular residual disease in stage I\u2013III non-small cell lung cancer patients treated with definitive radiotherapy","volume":"13","author":"Lebow","year":"2023","journal-title":"Front Oncol"},{"key":"2026080609160870300_bib18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"2026080609160870300_bib19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat Med"},{"key":"2026080609160870300_bib20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","article-title":"The evolving landscape of biomarker testing for non-small cell lung cancer in Europe","volume":"154","author":"Kerr","year":"2021","journal-title":"Lung Cancer"},{"key":"2026080609160870300_bib21","doi-asserted-by":"publisher","first-page":"100767","DOI":"10.1016\/j.ctarc.2023.100767","article-title":"The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy","volume":"37","author":"Proulx-Rocray","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"2026080609160870300_bib22","doi-asserted-by":"publisher","first-page":"107293","DOI":"10.1016\/j.lungcan.2023.107293","article-title":"KRAS G12C in advanced NSCLC: prevalence, co-mutations, and testing","volume":"184","author":"Lim","year":"2023","journal-title":"Lung Cancer"},{"key":"2026080609160870300_bib23","doi-asserted-by":"publisher","first-page":"108058","DOI":"10.1016\/j.lungcan.2024.108058","article-title":"STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status","volume":"199","author":"De Giglio","year":"2025","journal-title":"Lung Cancer"},{"issue":"12_Supplement","key":"2026080609160870300_bib24","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1158\/1538-7445.am2022-3763","article-title":"Abstract 3763: detection of tumor-associated gene inactivation in clinical blood draws via cell-free DNA methylation profiling","volume":"82","author":"Chen","year":"2022","journal-title":"Cancer Res"},{"issue":"12_Supplement","key":"2026080609160870300_bib25","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1158\/1538-7445.am2022-3758","article-title":"Abstract 3758: accurate epigenomic estimates of circulating tumor fraction in large-scale clinical data","volume":"82","author":"Greenwald","year":"2022","journal-title":"Cancer Res"},{"issue":"7_Supplement","key":"2026080609160870300_bib26","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1158\/1538-7445.AM2023-3123","article-title":"Abstract 3123: a method for quantifying circulating tumor DNA level and molecular response using methylome sequencing","volume":"83","author":"Chen","year":"2023","journal-title":"Cancer Res"},{"key":"2026080609160870300_bib27","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","article-title":"KEGG: biological systems database as a model of the real world","volume":"53","author":"Kanehisa","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"2026080609160870300_bib28","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","article-title":"Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"35","author":"Bardia","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026080609160870300_bib29","doi-asserted-by":"publisher","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"2026080609160870300_bib30","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-15-0670","article-title":"Enhanced delivery of SN-38 to human tumor xenografts with an anti-trop-2\u2013SN-38 antibody conjugate (sacituzumab govitecan)","volume":"21","author":"Sharkey","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026080609160870300_bib31","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"MAbs"},{"key":"2026080609160870300_bib32","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"2026080609160870300_bib33","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"2026080609160870300_bib34","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1158\/1078-0432.CCR-23-3924","article-title":"Sacituzumab govitecan demonstrates efficacy across tumor trop-2 expression levels in patients with advanced urothelial cancer","volume":"30","author":"Loriot","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026080609160870300_bib35","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"2026080609160870300_bib36","doi-asserted-by":"publisher","first-page":"7149","DOI":"10.1158\/1538-7445.am2025-7149","article-title":"The role of TROP2 in the MoA of Dato-DXd and how it underpins the biologic rationale of the novel AI-guided biomarker TROP2 normalized membrane ratio","volume":"85","author":"Sung","year":"2025","journal-title":"Cancer Res"},{"key":"2026080609160870300_bib37","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1038\/s41591-025-03883-5","article-title":"First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial","volume":"31","author":"Hong","year":"2025","journal-title":"Nat Med"},{"key":"2026080609160870300_bib38","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","article-title":"Early assessment of lung cancer immunotherapy response via circulating tumor DNA","volume":"24","author":"Goldberg","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026080609160870300_bib39","doi-asserted-by":"publisher","first-page":"105226","DOI":"10.1016\/j.critrevonc.2026.105226","article-title":"Prognostic significance of circulating tumor DNA as a baseline or dynamic factor in advanced NSCLC without oncogenic drivers: a systematic review and meta-analysis","volume":"221","author":"Andersen","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026080609160870300_bib40","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","article-title":"Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers","volume":"18","author":"Dogan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2026080609160870300_bib41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.lungcan.2013.07.013","article-title":"Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice","volume":"82","author":"Yamaguchi","year":"2013","journal-title":"Lung Cancer"},{"key":"2026080609160870300_bib42","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non\u2013small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026080609160870300_bib43","doi-asserted-by":"publisher","first-page":"194","DOI":"10.15698\/cst2025.08.311","article-title":"Datopotamab deruxtecan induces hallmarks of immunogenic cell death","volume":"9","author":"Forveille","year":"2025","journal-title":"Cell Stress"},{"key":"2026080609160870300_bib44","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"2026080609160870300_bib45","doi-asserted-by":"publisher","first-page":"113295","DOI":"10.1016\/j.celrep.2023.113295","article-title":"KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance","volume":"42","author":"Zavitsanou","year":"2023","journal-title":"Cell Rep"},{"key":"2026080609160870300_bib46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s10555-025-10245-7","article-title":"Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy","volume":"44","author":"Ramos-Ram\u00edrez","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"2026080609160870300_bib47","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0079-6603(06)81005-6","article-title":"Repair of topoisomerase I-mediated DNA damage","volume":"81","author":"Pommier","year":"2006","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"2026080609160870300_bib48","doi-asserted-by":"publisher","first-page":"708294","DOI":"10.3389\/fonc.2021.708294","article-title":"DNA damage response and repair gene alterations increase tumor mutational burden and promote poor prognosis of advanced lung cancer","volume":"11","author":"Dai","year":"2021","journal-title":"Front Oncol"},{"key":"2026080609160870300_bib49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination\u2013related gene mutations across multiple cancer types","volume":"2","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2026080609160870300_bib50","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1158\/1078-0432.CCR-19-3529","article-title":"Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L) 1 immune checkpoint inhibition in non\u2013small cell lung cancer","volume":"26","author":"Ricciuti","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026080609160870300_bib51","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","article-title":"Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response\u2014final results from GeparSixto","volume":"29","author":"Loibl","year":"2018","journal-title":"Ann Oncol"},{"key":"2026080609160870300_bib52","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"New Eng J Med"},{"key":"2026080609160870300_bib53","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/bjc.1996.394","article-title":"Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity","volume":"74","author":"McLeod","year":"1996","journal-title":"Br J Cancer"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0070\/3813129\/crc-26-0070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/1875\/3819868\/crc-26-0070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/1875\/3819868\/crc-26-0070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:16:19Z","timestamp":1786022179000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/8\/1875\/787312\/Evaluation-of-Biomarkers-for-Sacituzumab-Govitecan"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0070","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33174706","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174727","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174715","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174703","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174709","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174718","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174697","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174730","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174685","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174724","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174712","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174700","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174688","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174721","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174682","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174694","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33174691","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8638438","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}